CBT-295

• Target :

  Interleukin|||TGF-beta/Smad

• Related Pathways :

  Immunology/Inflammation|||Stem Cells

• Bioactivity :

  CBT-295, an orally active autotaxin (ATX) inhibitor, effectively decreases inflammatory cytokines including TGF-?, TNF-?, and IL-6, along with the bile duct proliferation marker CK-19, and ameliorates liver fibrosis. The compound's ability to reverse liver fibrosis contributes to lowered ammonia levels in the blood and brain, which in turn reduces ammonia-induced neuroinflammation. CBT-295 shows potential for the study of liver cirrhosis and related encephalopathy.

• Molecular Formula :

  C18H20ClN3O

• Molecular Weight :

  329.82

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C